Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Clinical Trial of Teriparatide in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients diagnosed with osteoporosis~* Aged 55 or older~* Patients who are at high risk for fracture~Exclusion Criteria:~* History of metabolic bone disorders other than primary osteoporosis~* History of malignant neoplasm in the 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated.~* Severe or chronically disabling conditions other than osteoporosis

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): 20 micrograms for 104 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).